European Antitrust Agenda: EU’s Shift Away from U.S. Tech Giants Sparks Backlash Among European Rivals; Aramark Weighs UK Supreme Court Appeal

Welcome to The European Antitrust Agenda, our weekly overview of European tech and competition law developments. Key stories we’re following this week include: • EU’s effort to swap U.S. tech for European rivals is proving to be a bumpy ride • Scottish court squashes Aramark challenge • What else is happening

UPM/Sappi: EU Doubts Behavioral Remedies Can Resolve Competition Concerns, Sources Say

The European Commission is skeptical that behavioral remedies will be enough to address competition concerns over paper giants UPM-Kymmene and Sappi’s proposed €1.42 billion ($1.59 billion) joint...

Oct 13, 2026 Read Now >

Life & Annuity Industry: As Election Day Nears, NAIC Letter and CRS Report Shape Congressional Debate Around Regulation of PE-owned Insurance

The National Association of Insurance Commissioners (NAIC) on Sept. 24 outlined in a letter steps they have already taken and are pursuing to shore up regulation of the insurance industry. The letter...

Oct 12, 2026 Read Now >

Schneider/PTC: French Giant’s Bid Would Put U.S. Army’s Weapons Data System Under Foreign Owner with Deep China Ties

Schneider Electric’s (EPA: SU) $22.6 billion bid for Boston’s PTC (PTC) would put software that holds the U.S. Army’s weapons data under a French company with extensive operations in...

Oct 12, 2026 Read Now >

European Antitrust Agenda: EU’s Shift Away from U.S. Tech Giants Sparks Backlash Among European Rivals; Aramark Weighs UK Supreme Court Appeal

RELATED ARTICLES | Antitrust Policy

UPM/Sappi: EU Doubts Behavioral Remedies Can Resolve Competition Concerns, Sources Say

Life & Annuity Industry: As Election Day Nears, NAIC Letter and CRS Report Shape Congressional Debate Around Regulation of PE-owned Insurance

Schneider/PTC: French Giant’s Bid Would Put U.S. Army’s Weapons Data System Under Foreign Owner with Deep China Ties

FILTER BY

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.